(1S,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(4-hydroxy-3,3-dimethyl-4-oxo-butanoyl)oxy-1-isopropyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (1S,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(4-hydroxy-3,3-dimethyl-4-oxo-butanoyl)oxy-1-isopropyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
• 英文别名: (1S,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-propan-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
• 化学式: C₃₆H₅₈O₆
• 分子量: 586.853
• InChiKey: QZZYICVSLLLMPB-WRFMNRASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (1S,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-propan-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid 、 chloroform methanol 在 水合甲醇 作用下， 生成 (1S,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(4-hydroxy-3,3-dimethyl-4-oxo-butanoyl)oxy-1-isopropyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
  参考文献：
  名称：

  Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein

  摘要：

  本文介绍了通过破坏病毒Gag衣壳（CA）蛋白（p24）从CA-间隔肽1（SP1）蛋白前体（p25）的处理来抑制HIV-1复制的方法。包括含有Gag p25蛋白中突变的氨基酸序列，该突变导致二甲基琥珀酰基莽草酸或二甲基琥珀酰基莽草素对p25到p24处理的抑制减少，编码这种突变序列的多核苷酸和选择性结合这种突变序列的抗体。还包括抑制HIV Gag蛋白的蛋白水解加工的方法、抑制性化合物和发现靶向蛋白水解加工的抑制性化合物的方法。在一种实施方式中，这些化合物通过结合Gag而不是蛋白酶酶抑制剂，抑制HIV蛋白酶酶与Gag的相互作用。在另一种实施方式中，包含Gag蛋白水解割位区域突变的病毒或重组蛋白可用于筛选试验，以识别靶向蛋白水解加工的化合物。

  公开号：

  US07537765B2

文献信息

• Anti-AIDS agents—XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives
  作者：Fumio Hashimoto、Yoshiki Kashiwada、L.Mark Cosentino、Chin-Ho Chen、Patricia E. Garrett、Kuo-Hsiung Lee

  DOI：10.1016/s0968-0896(97)00158-2

  日期：1997.12

  lupane-type triterpenoic acid derivatives were synthesized and evaluated for their inhibitory activity against HIV-1 replication in acutely infected H9 cells, based on the fact that betulinic acid (1) and dihydrobetulinic acid (9) were identified as anti-HIV agents. Among the derivatives, 3-O-(3',3'-dimethylsuccinyl)-betulinic acid (3) and 3-O-(3',3'-dimethylsuccinyl)-dihydrobetulinic acid (11) both demonstrated

  基于以下事实，合成了两个系列的卢烷型三萜酸衍生物，并评估了其在抗急性感染的H9细胞中对HIV-1复制的抑制活性，这是基于将桦木酸（1）和二氢白菜酸（9）鉴定为抗HIV的事实。代理商。在这些衍生物中，3-O-（3'，3'-二甲基琥珀酰基）-丁二酸（3）和3-O-（3'，3'-二甲基琥珀酰基）-二氢丁二酸（11）均显示出极强的抑制活性EC50值<3.5 x 10（-4）microM，并且显着的体外治疗指数（TI）值分别为20,000和14,000。3-O-（3'，3'-二甲基戊二芳基）-贝丁酸（4）和-二氢贝丁酸（12）3-O-二甘醇-丁二酸（5）和-二氢贝丁酸（13）和3-O-戊二酰-丁二酸（6）也是有效的HIV复制抑制剂，EC50值为0.04至2.3 x 10（-3） ）的microM和TI值在292至2344之间。此外，化合物11和12在单核细胞系和外周血单核细胞中也具有抗HIV复制的活
• Inhibition of Hiv-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein
  申请人：Salzwedel Karl

  公开号：US20080200550A1

  公开（公告）日：2008-08-21

  Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

  抑制HIV-1繁殖的方法是通过破坏病毒Gag外壳蛋白（CA）蛋白（p24）从CA-间隔肽1（SP1）蛋白前体（p25）的处理来实现的。包括含有Gag p25蛋白中突变的氨基酸序列，该突变导致二甲基琥珀酰基齐墩果酸或二甲基琥珀酰基齐墩的p25到p24处理的抑制减少，编码这种突变序列的多核苷酸和选择性结合这种突变序列的抗体。还包括抑制方法、抑制化合物和发现靶向HIV Gag蛋白的蛋白酶解处理的抑制化合物的方法。在其中一种实施例中，这些化合物通过与Gag结合而不是与蛋白酶酶结合来抑制HIV蛋白酶酶与Gag的相互作用。在另一种实施例中，包含在Gag蛋白酶解割位区域中的突变病毒或重组蛋白可以用于筛选测定，以识别靶向蛋白酶解处理的化合物。
• Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein
  申请人：SALZWEDEL Karl

  公开号：US20080233559A1

  公开（公告）日：2008-09-25

  Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

  本文揭示了通过破坏病毒Gag外壳蛋白（CA）从CA-spacer肽1（SP1）蛋白前体（p25）中的处理来抑制HIV-1复制的方法。包括含有Gag p25蛋白中突变的氨基酸序列，该突变导致二甲基琥珀酰基白桦酸或二甲基琥珀酰基白桦醇对p25到p24的处理抑制减少，编码这种突变序列的多核苷酸以及选择性结合这种突变序列的抗体。还包括抑制，抑制性化合物和发现靶向HIV Gag蛋白的蛋白酶加工的抑制性化合物的方法。在一种实施方式中，这些化合物通过结合Gag而不是蛋白酶酶来抑制HIV蛋白酶酶与Gag的相互作用。在另一种实施方式中，包含在Gag蛋白酶剪切位点区域中的突变病毒或重组蛋白可以用于筛选测定，以识别靶向蛋白酶加工的化合物。
• Betulinic Acid and Dihydrobetulinic Acid Derivatives as Potent Anti-HIV Agents
  作者：Yoshiki Kashiwada、Fumio Hashimoto、L. Mark Cosentino、Chin-Ho Chen、Patricia E. Garrett、Kuo-Hsiung Lee

  DOI：10.1021/jm950922q

  日期：1996.1.1
• Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
  申请人：——

  公开号：US20040265320A1

  公开（公告）日：2004-12-30

  Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

  本文介绍了通过破坏病毒Gag外壳（CA）蛋白（p24）从CA-spacer肽1（SP1）蛋白前体（p25）的处理来抑制HIV-1复制的方法。包括含有Gag p25蛋白中突变的氨基酸序列，该突变导致二甲基琥珀酰基莽草酸或二甲基琥珀酰基莽草素抑制p25到p24处理的减少，编码这种突变序列的多核苷酸和选择性结合这种突变序列的抗体。还包括抑制HIV Gag蛋白的蛋白酶分解过程的方法，抑制性化合物和发现靶向蛋白酶分解的抑制性化合物的方法。在一种实施例中，这种化合物通过结合Gag蛋白酶解割位点而不是蛋白酶酶来抑制HIV蛋白酶酶与Gag的相互作用。在另一种实施例中，包含Gag蛋白酶解割位点区域的病毒或重组蛋白可以用于筛选试验，以识别靶向蛋白酶分解的化合物。